ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that it has completed the enrolment of the second Phase III trial evaluating microplasmin for the non-surgical treatment of eye disease. The trial TG-MV-007, which recruited patients both in [...]

An experimental drug, LX211 (LUVENIQ™; oral voclosporin), may become the first approved oral treatment capable of modifying the course of uveitis, a group of serious eye conditions inevitably associated with either severe vision loss or substantial morbidity from steroid use. Results of international Phase 2/3 clinical trials conducted by Lux Biosciences, to be the subject [...]

A team from City University London’s Optometry Department has won a commercial award from the Emerald proof of concept fund, after pitching to a ‘Dragon’s Den’ panel of judges. The award will help develop eyeVisor™: a portable, inexpensive, head-mounted instrument that could play a role in the screening and home monitoring of chronic eye conditions [...]

The European Council of Optometry and Optics (ECOO) has called for patients with Down’s Syndrome and their carers to ensure that vision needs are regularly monitored after new research into the structure of the eye in people with Down’s Syndrome has found significant differences from the norm.

As summer vacations begin, experts at Lighthouse International urge everyone to take eye safety seriously and prevent damage from the sun that could be permanent. Lighthouse International, based in New York City, is the 104 year old non-profit leader in vision health.